ADA Scientific Sessions 2026 Abstract

Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals among Patients with Type 2 Diabetes: Quantifying an Opportunity to Improve Treatment Benefits

By Vivian Fonseca, Mariam Girguis, Morten Donsmark, Paul Muntner

Study in peoplePopulations

The paper

Vivian Fonseca, Mariam Girguis, Morten Donsmark, Paul Muntner

New Orleans

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1706-P

doi.org/10.2337/db26-1706-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression